Cargando…

Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase

Inorganic anions inhibit the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) generally by coordinating to the active site metal ion. Cyanate was reported as a non-coordinating CA inhibitor but those erroneous results were subsequently corrected by another group. We review the anion CA inhibitors (...

Descripción completa

Detalles Bibliográficos
Autores principales: Nocentini, Alessio, Angeli, Andrea, Carta, Fabrizio, Winum, Jean-Yves, Zalubovskis, Raivis, Carradori, Simone, Capasso, Clemente, Donald, William A., Supuran, Claudiu T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901698/
https://www.ncbi.nlm.nih.gov/pubmed/33615947
http://dx.doi.org/10.1080/14756366.2021.1882453
_version_ 1783654411967397888
author Nocentini, Alessio
Angeli, Andrea
Carta, Fabrizio
Winum, Jean-Yves
Zalubovskis, Raivis
Carradori, Simone
Capasso, Clemente
Donald, William A.
Supuran, Claudiu T.
author_facet Nocentini, Alessio
Angeli, Andrea
Carta, Fabrizio
Winum, Jean-Yves
Zalubovskis, Raivis
Carradori, Simone
Capasso, Clemente
Donald, William A.
Supuran, Claudiu T.
author_sort Nocentini, Alessio
collection PubMed
description Inorganic anions inhibit the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) generally by coordinating to the active site metal ion. Cyanate was reported as a non-coordinating CA inhibitor but those erroneous results were subsequently corrected by another group. We review the anion CA inhibitors (CAIs) in the more general context of drug design studies and the discovery of a large number of inhibitor classes and inhibition mechanisms, including zinc binders (sulphonamides and isosteres, dithiocabamates and isosteres, thiols, selenols, benzoxaboroles, ninhydrins, etc.); inhibitors anchoring to the zinc-coordinated water molecule (phenols, polyamines, sulfocoumarins, thioxocoumarins, catechols); CAIs occluding the entrance to the active site (coumarins and derivatives, lacosamide), as well as compounds that bind outside the active site. All these new chemotypes integrated with a general procedure for obtaining isoform-selective compounds (the tail approach) has resulted, through the guidance of rigorous X-ray crystallography experiments, in the development of highly selective CAIs for all human CA isoforms with many pharmacological applications.
format Online
Article
Text
id pubmed-7901698
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-79016982021-03-04 Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase Nocentini, Alessio Angeli, Andrea Carta, Fabrizio Winum, Jean-Yves Zalubovskis, Raivis Carradori, Simone Capasso, Clemente Donald, William A. Supuran, Claudiu T. J Enzyme Inhib Med Chem Review Article Inorganic anions inhibit the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) generally by coordinating to the active site metal ion. Cyanate was reported as a non-coordinating CA inhibitor but those erroneous results were subsequently corrected by another group. We review the anion CA inhibitors (CAIs) in the more general context of drug design studies and the discovery of a large number of inhibitor classes and inhibition mechanisms, including zinc binders (sulphonamides and isosteres, dithiocabamates and isosteres, thiols, selenols, benzoxaboroles, ninhydrins, etc.); inhibitors anchoring to the zinc-coordinated water molecule (phenols, polyamines, sulfocoumarins, thioxocoumarins, catechols); CAIs occluding the entrance to the active site (coumarins and derivatives, lacosamide), as well as compounds that bind outside the active site. All these new chemotypes integrated with a general procedure for obtaining isoform-selective compounds (the tail approach) has resulted, through the guidance of rigorous X-ray crystallography experiments, in the development of highly selective CAIs for all human CA isoforms with many pharmacological applications. Taylor & Francis 2021-02-21 /pmc/articles/PMC7901698/ /pubmed/33615947 http://dx.doi.org/10.1080/14756366.2021.1882453 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Nocentini, Alessio
Angeli, Andrea
Carta, Fabrizio
Winum, Jean-Yves
Zalubovskis, Raivis
Carradori, Simone
Capasso, Clemente
Donald, William A.
Supuran, Claudiu T.
Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase
title Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase
title_full Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase
title_fullStr Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase
title_full_unstemmed Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase
title_short Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase
title_sort reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901698/
https://www.ncbi.nlm.nih.gov/pubmed/33615947
http://dx.doi.org/10.1080/14756366.2021.1882453
work_keys_str_mv AT nocentinialessio reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase
AT angeliandrea reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase
AT cartafabrizio reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase
AT winumjeanyves reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase
AT zalubovskisraivis reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase
AT carradorisimone reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase
AT capassoclemente reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase
AT donaldwilliama reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase
AT supuranclaudiut reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase